Biotech Jonathan Wosen STAT Plus: Mirum’s Chenodal succeeds in late-stage trial for rare metabolic disorder
Biotech Adam Feuerstein STAT Plus: The biotech scorecard for the fourth quarter: 16 stock-moving events to watch
In the Lab Jason Mast STAT Plus: Can the world still invent an HIV vaccine? Progress in one area creates new problem
Biotech Allison DeAngelis STAT Plus: What will Novo’s VC do with its influx of cash? Don’t expect obesity investments
Biotech Damian Garde STAT Plus: FDA advisers vote overwhelmingly against ALS treatment from BrainStorm
Biotech Matthew Herper STAT Plus: U.S. government’s next-gen Covid effort gives small biotech up to $433 million
Biotech Jason Mast STAT Plus: Gene therapy death was caused by an unknown risk of the virus used, study suggests
Exclusive Mario Aguilar and Matthew Herper STAT Plus: Biogen shutters digital health group, nixes Apple study, as part of cost cuts
Politics Sarah Owermohle STAT Plus: With Menendez indictment, pharmaceutical industry could lose a key ally
Biotech Robert Weisman — Boston Globe and Jon Chesto — Boston Globe STAT Plus: Cambridge announced as ‘investor catalyst’ hub for ARPA-H
Biotech Damian Garde STAT Plus: Intercept, once a biotech trailblazer, sells itself for less than $1 billion
Biotech Andrew Joseph STAT Plus: Early data are promising for autoimmune disease drug from Roivant Sciences’ Immunovant
Biotech Jonathan Wosen STAT Plus: Ionis inches toward first solo drug launch with late-stage trial success for rare genetic disease therapy
First Opinion Leah Christl STAT Plus: The problem with potential changes to the biosimilar regulatory framework
Biotech Damian Garde STAT Plus: BrainStorm’s case for ALS approval relies on ‘grossly deficient’ data, FDA finds
Biotech Andrew Joseph STAT Plus: Breast cancer drug from AstraZeneca, Daiichi hits goal in late-stage trial
Health Tech Lizzy Lawrence STAT Plus: FDA panel votes against GLP-1 therapy from former diabetes unicorn Intarcia
Biotech Jonathan Saltzman — Boston Globe STAT Plus: Thermo Fisher just opened a $180 million plant. Executives already are talking about expanding.
Biotech Jason Mast STAT Plus: Travere kidney drug narrowly fails confirmatory trial following FDA approval
Adam's Take Adam Feuerstein STAT Plus: The Apellis eye drug rebound accelerates. This time, it’s a competitor falling behind
Biotech Jonathan Wosen STAT Plus: Biotech lab-space demand falls sharply as industry’s ‘sugar high’ turns into a ‘reset’
Exclusive Jason Mast STAT Plus: David Liu startup to focus on getting CRISPR therapy to hard-to-reach cells
Biotech Allison DeAngelis STAT Plus: Machine learning biotech raises $273 million in rare successful late-stage round
Biotech Damian Garde STAT Plus: FDA panel endorses Alnylam’s heart drug — after picking apart its supporting data